The FDA has granted accelerated approval to Tzield (teplizumab) to delay the decline in endogenous insulin production in children ages 8 to 17 years recently diagnosed with stage 3 Type 1 diabetes.
The approval makes Tzield the first disease-modifying therapy approved in the U.S. for patients recently diagnosed with stage 3 Type 1 diabetes, according to a June 13 news release from drugmaker Sanofi. The indication was supported by results from the Protect phase 3 study and data from a broader clinical development program involving more than 900 patients who received the therapy.
In the study, patients receiving Tzield experienced a slower decline in insulin production than those receiving a placebo. The FDA granted the indication under its accelerated approval pathway based on evidence of reduced C-peptide decline.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
